1. Outcome of patients after market withdrawal of thioridazine: a retrospective analysis in a nationwide cohort.
- Author
-
Purhonen M, Koponen H, Tiihonen J, and Tanskanen A
- Subjects
- Antipsychotic Agents administration & dosage, Antipsychotic Agents therapeutic use, Cohort Studies, Databases, Factual, Finland, Hospitalization statistics & numerical data, Hospitalization trends, Humans, Length of Stay, Middle Aged, Pharmacoepidemiology, Retrospective Studies, Risk Assessment, Schizophrenia epidemiology, Thioridazine administration & dosage, Thioridazine therapeutic use, Treatment Outcome, Adverse Drug Reaction Reporting Systems, Antipsychotic Agents adverse effects, Drug Utilization Review, Product Recalls and Withdrawals, Schizophrenia drug therapy, Thioridazine adverse effects
- Abstract
Objective: Thioridazine is a first-generation antipsychotic drug that was withdrawn from the market worldwide in 2005. The outcome of clinically stable schizophrenia patients who used thioridazine before market withdrawal was evaluated., Methods: Nationwide registers in Finland were utilized to study thioridazine use, hospitalization rate and length of hospital stay., Results: Although thioridazine use continued to diminish year after year, the hospitalization rate remained constant until the withdrawal year of 2005, when the percentage of patients hospitalized for schizophrenia doubled., Conclusion: The market withdrawal of thioridazine predisposed many stable patients towards psychotic relapses. In order to minimize this kind of risk, an overall risk-benefit assessment and a clear-cut plan for the replacement of an antipsychotic should be established before market withdrawal., (Copyright © 2012 John Wiley & Sons, Ltd.)
- Published
- 2012
- Full Text
- View/download PDF